Spyre Therapeutics Inc (SYRE)

07:08 AM

Will Spyre Therapeutics Inc. stock benefit from AI tech trendsTriple-digit returns - jammulinksnews.com

07:08 AM

06:44 AM

Is Spyre Therapeutics Inc. a good long term investmentHigh-impact stock picks - PrintWeekIndia

06:44 AM

Jul 24, 2025

What analysts say about Spyre Therapeutics Inc. stockOutstanding capital growth - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Spyre Therapeutics Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional

Jul 23, 2025

Jul 23, 2025

What drives Spyre Therapeutics Inc. stock priceRapid capital growth - jammulinksnews.com

Jul 23, 2025

Jul 20, 2025

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $53.40 - Defense World

Jul 20, 2025

Jul 17, 2025

Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - beatles.ru

Jul 17, 2025

Jul 15, 2025

How Spyre Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - Newser

Jul 15, 2025

Jul 15, 2025

What makes Spyre Therapeutics Inc. stock price move sharplyPotential Rocket List - Newser

Jul 15, 2025

Jul 15, 2025

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation - Yahoo Finance

Jul 15, 2025

Jul 15, 2025

This Spyre Therapeutics Insider Reduced Their Stake By 55% - 富途牛牛

Jul 15, 2025

Jul 03, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - TradingView

Jul 03, 2025

Jun 26, 2025

GAMMA Investing LLC Purchases New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 26, 2025

Jun 23, 2025

Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE) - The Globe and Mail

Jun 23, 2025

Jun 18, 2025

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha

Jun 18, 2025

Jun 17, 2025

Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha

Jun 17, 2025

Jun 17, 2025

Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025

Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus

Jun 17, 2025

Jun 17, 2025

Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener

Jun 17, 2025

Jun 17, 2025

Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks

Jun 17, 2025

Jun 17, 2025

Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus

Jun 17, 2025

Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire

Jun 17, 2025

Jun 16, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus

Jun 16, 2025

Jun 16, 2025

Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan

Jun 16, 2025

Jun 16, 2025

Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 16, 2025

Jun 11, 2025

California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 11, 2025

Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 10, 2025

Jun 09, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener

Jun 09, 2025